Published: November 2017 | Report Code: LS10974 | Available Format: | Pages: 105 |
Note: This report can also be updated as of date and delivered within 1-2 working days of purchase confirmation
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
Chapter 3. Executive Summary
Chapter 4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Hereditary Angioedema (HAE) Therapeutics Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company
Chapter 5. Hereditary Angioedema (HAE) Therapeutics Pipeline Analysis by Phase (2017)
5.1 Phase III: Drug profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase II: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase I: Drug profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Clinical Trials
5.3.4 Clinical Results
5.3.5 Strategic Development
5.3.6 Designation
5.3.7 Grants
5.3.8 Patent
5.3.9 Technology
5.4 Pre-Clinical: Drug profiles
5.4.1 Pre-Clinical Study
5.4.2 Pre-Clinical Results
5.4.3 Strategic Development
5.4.4 Designation
5.4.5 Grants
5.4.6 Patent
5.4.7 Technology
5.5 Discovery: Drug profiles
5.5.1 Strategic Development
5.5.2 Designation
5.5.3 Grants
5.5.4 Patent
5.5.5 Technology
Chapter 6. Clinical Trials Analysis
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status
Chapter 7. Competitive Landscape
7.1 Key Players Benchmarking for Hereditary Angioedema (HAE) Therapeutics Pipeline
7.2 SWOT Analysis of Hereditary Angioedema (HAE) Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats
Chapter 8. Company Profiles
8.1 Business Overview
8.2 Pipeline Products
Chapter 9. Appendix
9.1 Abbreviations
9.2 Related Reports
LIST OF TABLES
PIPELINE ANALYSIS OF HEREDITARY ANGIOEDEMA (HAE) THERAPEUTICS, BY COMPANY (2017)
DESCRIPTION OF PHASE III DRUG CANDIDATES
CLINICAL TRIALS OF PHASE III DRUG CANDIDATES
DESCRIPTION OF PHASE II DRUG CANDIDATES
CLINICAL TRIALS OF PHASE II DRUG CANDIDATES
DESCRIPTION OF PHASE I DRUG CANDIDATES
CLINICAL TRIALS OF PHASE I DRUG CANDIDATES
DESCRIPTION OF PRE-CLINICAL DRUG CANDIDATES
DESCRIPTION OF DISCOVERY DRUG CANDIDATES
COMPANIES - AT A GLANCE
LIST OF FIGURES
RESEARCH METHODOLOGY
SPLIT OF PRIMARY AND SECONDARY RESEARCH
BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT
BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE
HAE THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
HAE THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2017)
HAE THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)
BREAKDOWN OF CLINICAL TRIALS, BY REGION
BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS
KEY PLAYERS BENCHMARKING
SWOT ANALYSIS